Wall Street analysts forecast that Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) will report earnings per share (EPS) of ($3.47) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Intercept Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($4.08) and the highest estimate coming in at ($2.97). Intercept Pharmaceuticals reported earnings per share of ($4.84) in the same quarter last year, which suggests a positive year over year growth rate of 28.3%. The business is expected to issue its next earnings results on Thursday, February 22nd.

On average, analysts expect that Intercept Pharmaceuticals will report full year earnings of ($13.79) per share for the current fiscal year, with EPS estimates ranging from ($14.77) to ($13.03). For the next financial year, analysts anticipate that the business will post earnings of ($11.99) per share, with EPS estimates ranging from ($15.66) to ($8.15). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Intercept Pharmaceuticals.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 152.78%. The firm had revenue of $41.33 million for the quarter, compared to the consensus estimate of $36.95 million. During the same period in the previous year, the firm posted ($3.59) earnings per share. The firm’s revenue was up 697.9% on a year-over-year basis.

ICPT has been the topic of a number of research analyst reports. Royal Bank Of Canada initiated coverage on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $244.00 price objective on the stock. Laidlaw lowered their price objective on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating on the stock in a research report on Friday, September 22nd. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Wedbush reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Finally, Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and an average price target of $153.76.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded up $0.84 on Friday, reaching $62.47. 1,146,749 shares of the company were exchanged, compared to its average volume of 1,186,875.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/03/intercept-pharmaceuticals-inc-icpt-expected-to-post-earnings-of-3-47-per-share.html.

In related news, CEO Mark Pruzanski sold 1,532 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the transaction, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at $5,379,703.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,069 shares of company stock valued at $325,974. Corporate insiders own 9.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. raised its stake in Intercept Pharmaceuticals by 100.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after purchasing an additional 15,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after buying an additional 57,149 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of Intercept Pharmaceuticals by 9.0% in the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 178 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its stake in shares of Intercept Pharmaceuticals by 85.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after buying an additional 3,136 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Intercept Pharmaceuticals by 12.8% in the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after buying an additional 16,392 shares in the last quarter. Hedge funds and other institutional investors own 82.81% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get a free copy of the Zacks research report on Intercept Pharmaceuticals (ICPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.